A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-29. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Periodic acid-Schiff (PAS) and immunohistochemical staining may also be used for diagnosis. Currently, there is no cure for Urbach–Wiethe disease, although there are ways to individually treat many of its symptoms. The discovery of the mutations of the ECM1 gene has opened the possibility of gene therapy or a recombinant ECM1 protein for Urbach–Wiethe disease treatment, but neither of these options are currently available. Some researchers are examining patients with Urbach–Wiethe disease to learn more about other conditions that exhibit similar neurological symptoms, such as autism.
To commemorate the occasion, the airline named the McDonnell Douglas MD-11 operating the inaugural flight Elvis 1 and gave each passenger gifts, among them a small bottle of Jack Daniel's whiskey. In preparation for the flight, the airport had constructed a new customs facility. In 1997, Northwest acquired Express Airlines I, a regional carrier that operated under the Northwest Airlink brand, and shifted its headquarters to Memphis. The airport served 11.8 million travelers in 2000. The Memphis–Shelby County Airport Authority expanded the facilities. The passenger terminal was enlarged five times between 1986 and 1999. Northwest and the airport authority worked together on the fifth project. They added 15 gates to Concourse A for Express I's new 50-seat Bombardier CRJs. Other upgrades included a post-security corridor linking Concourses B and C, a new lounge, and faster ticket counters. A third parallel runway opened in 1997. Three years later, the middle runway was rebuilt and lengthened to 11,120 feet (3,390 m). Dubbed the World Runway, it enabled KLM to take off from Memphis with a full cabin in hot conditions and FedEx to carry more cargo.
=== Vegetarian HDR and MARC === The Humanitarian Daily Ration (HDR) is a self-contained Halal meal designed to be given to refugees and other displaced people. It is designed to feed a person for a full day, and the menus are intended to be palatable to many religious and cultural tastes. To meet this goal, no animal products or by-products, no alcohol or alcohol-based products, and minimal dairy products are used in their production. It is otherwise created and packaged much like MREs; feedback from the Afghanistan campaign led to the interior packing being reinforced to withstand being air-dropped, as the packets sometimes ruptured on impact. The outer bag is tinted a high-visibility red or yellow and has an American flag and a picture of a person eating out of the bag with a spoon. There are usually instructions printed on it in English and one or more local languages as well. The Meal, Alternative Regionally Customized (MARC) is a self-contained, shelf-stable meal developed by U.S. Army Soldier and Biological Chemical Command (SBCCOM)/Natick, Individual Combat Ration Team (ICRT), Combat Feeding Directorate (CFD). MARCs were developed specifically for detainees at Guantanamo Bay, and have since found wider spread use, notably Iraq and Afghanistan. MARC meals are entirely vegetarian as an easy way to prevent conflicts with culturally "prohibited products" (Islam and Judaism forbidding pork, Hindus avoiding beef, etc). They are neither Kosher nor Halal certified.
==== Donations to campaign ==== In February 2024, Bloomberg News reported that Newsom pushed for an exemption for businesses that bake and sell bread in AB 1228, a bill that raises the state's minimum wage for fast food workers to $20 per hour. The exemption included 24 Panera Bread bakery-cafes owned by Greg Flynn, a businessman who donated $100,000 and $64,800 to Newsom's campaigns over the years. Republican lawmakers called for an investigation into the unusual exemption. When reporters asked him about the exemption, Newsom said: "That's a part of the sausage making. We went back and forth, and that was part of the negotiation. That's the nature of negotiation ... That was all part of the give and take and that was the collective wisdom of the legislature and ultimately led to my signature." In September 2024, the Los Angeles Times reported that Newsom had signed AB 3206 into law, carving out an exception to the state's last call alcohol law for one specific venue, Intuit Dome, owned by former Microsoft CEO Steve Ballmer. Ballmer's wife, Connie Ballmer, donated $1 million to the Newsom campaign in 2021. Ethics experts criticized the bill for exclusively benefiting a major donor to Newsom. "It's certainly going to become an issue for his opponents and critics to point to the fact that he seemed to provide a special favor to a wealthy sports franchise owner and its facility and its wealthy fans. It just doesn't look good", said John Pelissero, director of government ethics at Santa Clara University.
Sources: en.wikipedia.org
We thought it fitting that there be an element named for the Russian chemist Dmitri Mendeleev, who had developed the periodic table. In nearly all our experiments discovering transuranium elements, we'd depended on his method of predicting chemical properties based on the element's position in the table. But in the middle of the Cold War, naming an element for a Russian was a somewhat bold gesture that did not sit well with some American critics. Being the first of the second hundred of the chemical elements, it was decided that the element would be named "mendelevium" after the Russian chemist Dmitri Mendeleev, father of the periodic table. Because this discovery came during the Cold War, Seaborg had to request permission from the government of the United States to propose that the element be named for a Russian, but it was granted. The name "mendelevium" was accepted by the International Union of Pure and Applied Chemistry (IUPAC) in 1955 with symbol "Mv", which was changed to "Md" in the next IUPAC General Assembly (Paris, 1957).
Member, National Teaching School Council and Lead, South-West National Teaching School Council Representative. For services to Education. Chitralekha Bolar. Dancer, Choreographer and Teacher. For services to South Asian Dance. Emily Josephine Bolton. Founder, Our Future. For services to Social Mobility. Thomas Stewart Bosworth. For services to Race Walking. Richard James Bottomley. Headteacher, Bradford Alternative Provision Academy. For services to Vulnerable Children and Young People. James David Boyes. Team UK Gold Medal Winner, WorldSkills UK. For services to Further Education. Nicholas Boys Smith. Founder and Director, Create Streets and Chair, Office for Place. For services to Planning and Design. Samuel James Braddick. For services to the community in Gillingham, Dorset. Mark Richard Brett. For services to Charity and to the community in Wallingford, Oxfordshire. Anne Brewster. 50 Plus Lead, Yorkshire and the Humber, Department for Work and Pensions. For services to the Welfare of Older People. Debbie Hazel Brown. Advanced Nurse Practitioner and Clinical Director, Lewisham Community Education Provider Network Training Hub. For services to Nursing and the NHS. Joanna Esther Brown (Joanna Cram). Lately Chair, Scottish Osteopathic Society. For services to Musculoskeletal Healthcare in Scotland. Patricia Ann Brown. Director and Founder, Central. For services to the Built Environment. Penelope Jane Brown. For services to Charity and to the community in Salisbury, Wiltshire. Sara Margaret Browne (Sally Browne).
=== Infection === If a chronic wound becomes more painful this is a good indication that it is infected. A lack of pain however does not mean that it is not infected. Other methods of determination are less effective.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.